Page 8 - Celularity Inc News Today

Celularity’s Pre-Request for Designation is based on data demonstrating 100 percent biochemical characterization of the product Celularity intends to submit 510 pre-market notification to the... | April 3, 2023

Celularity Inc. (NASDAQ:CELU – Get Rating) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 4,750,000 shares, a growth of 38.1% from the February 28th total of 3,440,000 shares. Currently, 9.2% of the company’s shares are sold short. Based on […]

Celularity Inc. (NASDAQ:CELUW – Get Rating) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 8,700 shares, an increase of 19.2% from the February 28th total of 7,300 shares. Based on an average trading volume of 19,300 shares, the short-interest ratio is currently […]

/PRNewswire/ -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a biotechnology company developing placental-derived allogenic cell therapies and biomaterial...

AD Ports Logistics, subsidiary of AD Ports Group’s Logistics Cluster, chosen as the Exclusive Distributor for United Arab Emirates, Qatar, Bahrain, Oman, Kuwait and Egypt Product distribution... | March 28, 2023

Adoptive Cellular Immunotherapy Market

Chimeric Antigen Receptor Cell Therapy Market­

NioCorp Developments Ltd. announced that following completion of the Business Combination, Dean C. Kehler and Michael G. Maselli have been appointed to the NioCorp board of directors, joining the... | March 19, 2023

/PRNewswire/ -- NioCorp Developments Ltd. ("NioCorp" or the "Company") (TSX: NB; OTCQX: NIOBF) today announced the completion of its previously announced...

Gainers ObsEva SA (NASDAQ:OBSV) rose 93.1% to $0.2047 in pre-market trading after dropping over 12% on Thursday. ObsEva recently announced strat...